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OBJECTIVE: To determine if certain diagnoses and
comorbidities inﬂuence the risk of hospitalization for
angina patients. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLinkTM database, a U.S. employer claims database 
consisting of more than 1.8 million covered lives, with
linked medical and pharmacy claims for employees, depen-
dents, and retirees from 1991 forward. Patients were diag-
nosed with angina in the period March 1, 1999 to
February 29, 2000. Unstable angina patients were placed
in a single cohort. Stable angina patients were further clas-
siﬁed based on the presence of hypertension, congestive
heart failure (CHF), diabetes, or other heart disease in the
36 months preceding their angina diagnosis.
RESULTS: 125,453 patients met the inclusion criteria—
32,672 with unstable angina and 92,781 with stable
angina. Patients with unstable angina were signiﬁcantly
more likely to be hospitalized (53.3%) than patients 
with stable angina (27.3%) (p < 0.001). When compar-
ing unstable to stable angina patients with comorbid con-
ditions, patients with unstable angina were more likely 
to be hospitalized than stable angina patients, regardless
of the combination of comorbidities in stable angina
patients (odds ratios between 1.20 and 10.47). Stable
angina patients with comorbid hypertension, diabetes,
and CHF had the most similar risk of hospitalization
compared to unstable angina patients, but still were sig-
niﬁcantly less likely to be hospitalized (OR = 0.83, 95%
CI = 0.79, 0.87). Unstable angina patients had the highest
likelihood of hospitalization compared to patients with
stable angina and no comorbidities (OR = 10.47, 95% CI
= 9.76, 11.22). Among stable angina patients, hospital-
ization rates were highest for patients with comorbid
CHF (ranging from 36.6% for patients with CHF only 
to 48.7% for patients with CHF, hypertension, and 
diabetes).
CONCLUSIONS: Patients with unstable angina were 
signiﬁcantly more likely than stable angina patients to 
be hospitalized, even if the stable angina patients had a
number of complicating comorbid conditions. Presence 
of unstable angina greatly increased the risk of 
hospitalization.
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The National Institutes of Health’s Adult Treatment Panel
III (ATP-III) guidelines deﬁne the population of hyperc-
holesterolemic patients for whom drug therapy is sug-
gested. A wide body of evidence indicates that elevated
low-density lipoprotein (LDL-C) is a major risk factor for
coronary heart disease (CHD). Thus, the ATP-III guide-
lines target LDL-C levels for reduction in hypercholes-
terolemic patients in an effort to reduce CHD risk. The
drug of choice is an HMG-CoA Reductase Inhibitor
(statin), which has demonstrated effectiveness in reducing
LDL-C.
OBJECTIVES: To determine if the relative cost-
effectiveness of the three most commonly prescribed
statins is affected by the initial LDL-C and ATP-III goals. 
METHODS: A Monte Carlo simulation was used to
model therapeutic course to target using data from pub-
lished trials including (pre-treatment LDL-C distribu-
tions, expected LDL-C reduction by drug and dose and
ATP-III LDL-C goals). Data from this model were entered
into a cost-effectiveness analysis model in Data 4.0
(TreeAge Software, Inc, 2001). One-way sensitivity 
analyses were conducted upon pre-treatment LDL-C 
distribution, statin performance, and costs of: drugs, 
time away from work/home, ofﬁce visits, laboratory tests
and mono-therapy failure.
RESULTS: Atorvastatin dominated the model, having 
the lowest drug cost and failure rate, regardless of initial
LDL-C level or ATP-III guideline goal. Base case (mean
LDL-C 188.9mg/dl [SD 24.0] and goal LDL-C of 
100mg/dl) cost-effectiveness ratios for atorvastatin, sim-
vastatin and pravastatin were $(US) 1,721, $(US) 3,641
and $(US) 22,029 respectively. Alternative case (mean
LDL-C 149.6mg/dl [SD 16.8] and goal LDL-C of 100
mg/dl) cost-effectiveness ratios for atorvastatin, simvas-
tatin and pravastatin were $(US) 965, $(US) 1,552 and
$(US) 2,498 respectively.
CONCLUSIONS: Atorvastatin was the most cost-
effective treatment among the tested statins. Cost-
effectiveness rankings were insensitive to all tested vari-
ables. Cost-effectiveness was primarily determined by the
performance characteristics of each drug and drug cost.
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It is well known that surgery performed under general
anesthesia commonly results in hypothermia. Surgical
hypothermia is a serious, but preventable, condition. 
It is becoming increasingly important, however, to
provide decision-makers with evidence of the cost-
effectiveness as well as the clinical beneﬁt of preventive
measures.
OBJECTIVE: Using the hospital perspective, the out-
comes and cost-effectiveness of the Arctic Sun Model 
100 for the prevention of hypothermia in patients under-
going off-pump coronary artery bypass surgery is
explored. 
